SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
US Supreme Court blocks bid to overturn lower court ruling | District court found in 2023 that the generic would infringe patents owned by a Bausch subsidiary | Blockbuster drug Xifaxan is used to treat IBS with diarrhoea, and a liver-related brain disorder.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
2 November 2023 District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.
2 November 2023 District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.
2 November 2023 District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.